243 related articles for article (PubMed ID: 36657359)
1. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
Aboumatar S; Krishnaiengar SR; Cantu D; Zhang Y; Grinnell T
Clin Neurol Neurosurg; 2023 Feb; 225():107552. PubMed ID: 36657359
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures.
Hixson J; Gidal B; Pikalov A; Zhang Y; Mehta D; Blum D; Cantu D; Grinnell T;
Epilepsy Res; 2021 Mar; 171():106561. PubMed ID: 33556737
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
Andermann E; Rosenfeld W; Penovich P; Rogin J; Cendes F; Carreño M; Ramsay RE; Ben-Menachem E; Gama H; Rocha F; Soares-da-Silva P; Tosiello R; Blum D; Grinnell T
Epilepsy Res; 2021 Jan; 169():106478. PubMed ID: 33338829
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
[TBL] [Abstract][Full Text] [Related]
6. Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results.
Cramer JA; Colman S; Anastassopoulos KP; Grinnell T; Mehta D; Williams GR
Epilepsy Behav; 2020 Nov; 112():107312. PubMed ID: 32801102
[TBL] [Abstract][Full Text] [Related]
7. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
[TBL] [Abstract][Full Text] [Related]
8. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
[TBL] [Abstract][Full Text] [Related]
9. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial.
Kirkham F; Auvin S; Moreira J; Gama H; Falcão AC; Rocha JF; Soares-da-Silva P
Epilepsy Behav; 2020 Apr; 105():106962. PubMed ID: 32151803
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures.
Costa R; Steinhoff B; Gama H; Ikedo F; Rocha JF; Soares-da-Silva P
Drugs Aging; 2018 Dec; 35(12):1109-1117. PubMed ID: 30387043
[TBL] [Abstract][Full Text] [Related]
12. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis.
Lattanzi S; Trinka E; Zaccara G; Striano P; Russo E; Del Giovane C; Silvestrini M; Brigo F
Drugs; 2022 Feb; 82(2):199-218. PubMed ID: 35061214
[TBL] [Abstract][Full Text] [Related]
13. Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses.
Mehta D; Davis M; Epstein AJ; Wensel B; Grinnell T; Williams GR
Neurol Ther; 2020 Dec; 9(2):585-598. PubMed ID: 32949379
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial.
Lee SK; Lee SA; Hong SB; Cho YW; Castilla-Fernández G; Fonseca MM; Moreira J; Gama H; Holenz J
Clin Transl Sci; 2024 May; 17(5):e13802. PubMed ID: 38787305
[TBL] [Abstract][Full Text] [Related]
15. Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.
Krauss G; Biton V; Harvey JH; Elger C; Trinka E; Soares da Silva P; Gama H; Cheng H; Grinnell T; Blum D
Epilepsy Res; 2018 Jan; 139():1-8. PubMed ID: 29127848
[TBL] [Abstract][Full Text] [Related]
16. Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures.
Altalib H; Grinnell T; Cantu D; Ikedo F; Vieira M; Zhang Y; Blum D
Epilepsia Open; 2022 Dec; 7(4):616-632. PubMed ID: 35908275
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and tolerability of adjunctive eslicarbazepine acetate in patients with focal to bilateral tonic-clonic seizures.
Chung S; Guirguis S; Cantu D; Moreira J; Magalhães LM; Hall D; Grinnell T
Epilepsy Res; 2024 Feb; 200():107285. PubMed ID: 38183687
[TBL] [Abstract][Full Text] [Related]
18. Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures.
Brandt C; Dimova S; Elmoufti S; Laloyaux C; Nondonfaz X; Klein P
Epilepsy Behav; 2023 Jan; 138():108967. PubMed ID: 36435010
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Ryvlin P; Dimova S; Elmoufti S; Floricel F; Laloyaux C; Nondonfaz X; Biton V
Epilepsia; 2022 Aug; 63(8):2024-2036. PubMed ID: 35582748
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
